Led · Series C · Jul 2026

Antares develops small modular reactors capable of producing roughly 100 kilowatts to 1 megawatt of electricity and designs its reactors to use TRISO fuel, which encapsulates uranium in carbon and ceramic shells. Its Mark-0 demonstration reactor reached criticality on June 4 at the Idaho National Laboratory. Antares is a finalist in the Pentagon’s Advanced Nuclear Power for Installations program and is pursuing deployments on Air Force bases in Colorado and Montana. The company plans to bring its first electricity-producing reactor online next year and targets military deployments in 2028. Financially, Antares has raised a total of $604 million to date, including a $96 million Series B in December and the $470 million Series C. The broader advanced nuclear sector faces challenges such as an immature U.S. supply chain and near-term cost competitiveness concerns; Lazard estimates new SMRs could cost about $214 per megawatt-hour, and Antares has not disclosed pricing.

Participated · Equity · Jul 2026

Integral provides Forward Deployed Privacy Services that embed privacy experts directly into customer data pipelines to perform entity-preserving remediation and continuous privacy risk assessment. Its methodology is grounded in peer-reviewed statistical disclosure limitation research and was initially validated in healthcare, life sciences, and health data marketplaces. Integral produces defensibility artifacts such as Expert Determinations under HIPAA or signed defensibility opinions tailored to context, enabling enterprises and data originators to commercialize or share sensitive datasets. The company supports AI labs, data platforms, vertical AI builders, and enterprises operating in regulated environments. Following a $25 million financing, Integral plans to expand its privacy engineering and statistical methodology teams, invest in linkage and continuous assessment infrastructure, and broaden go-to-market efforts across the real-world data economy.

Led · Series A · Jun 2026

Founded in 2024 by Thomas Mosen and Charles Englander and based in New York, Sea12 offers an AI-powered platform that connects data and automates complex back-office workflows. Its core product, the Sea12 Orchestrator, is an AI orchestration software designed for heavy industries including manufacturing, logistics, construction, and facilities management. The company has reported rapid adoption and counts clients such as Basden Steel, where it automates document processing and invoice management. Sea12 plans to use proceeds from its $25 million Series A to accelerate development of the Orchestrator and to scale operations beyond its initial sectors. The funding round was led by Caffeinated Capital.

Participated · Series B · Jun 2026

Founded in 2024 and based in Arlington, Va., Twenty develops AI-enabled, end-to-end systems intended to provide offensive cyber capabilities to the U.S. military and Intelligence Community. The company emphasizes pairing advanced AI and automation with human judgment, rigorous evaluation, controlled deployment, and mission alignment. Twenty has rapidly reached operational relevance and has attracted early backing from investors including General Catalyst and In-Q-Tel. After its $100 million Series B led by Accel at a $1 billion valuation, Twenty’s total funding stands at $138 million. Management said the new capital will be directed into research and engineering. The company positions itself as industrializing offensive cyber warfare for the United States and its allies.

Led · Series A · Jun 2026

Neion Bio’s core product is the Raptor™ platform, which leverages genetic engineering to restrict recombinant protein production to chicken eggs as a means to manufacture complex, glycosylated biologic proteins. Founded in 2024, the company is positioning the platform to address scalability, resiliency, capital efficiency, speed, and the ability to express difficult-to-manufacture molecules. Neion plans to expand its pipeline across biosimilars, innovative medicines, critical reagents, and animal health and to commercialize via partnerships, including a recently announced multi-product biosimilars co-development and supply agreement with a major pharmaceutical company. The company is advancing proprietary technologies intended to enable production at meaningful scale within days and to shorten iteration cycles for molecule screening and production. Financially, Neion completed an oversubscribed $23 million Series A to fund these platform and pipeline initiatives.